FierceBiotech: Alzheimer's disease
Latest Headlines
Lund researchers develop Alzheimer's-in-a-dish model
Animal models tend to leave a lot to be desired when it comes to Alzheimer's research. As a result, there's been considerable activity in developing an "Alzheimer's-in-a-dish" model, and investigators at Lund University in Sweden say they've been making progress on that front.
Could alpha secretase offer a better approach to fighting Alzheimer's?
Investigators at Mainz University say they've been gathering evidence to suggest that the alpha secretase enzyme could play a dual role in fighting Alzheimer's disease.
Biogen barrels toward Alzheimer's Phase III after a promising early signal
Biogen Idec is heralding hope in one of the industry's toughest fields, plotting a late-stage trial for an Alzheimer's disease treatment after charting some surprising positive results in an early study.
Alzheimer's 'breakthrough' simulates disease symptoms in brain cells
Investigators have claimed a breakthrough in the amyloid hypothesis, cultivating what they call "Alzheimer's-in-a-dish" that shows deposits of amyloid are indeed to blame for amyloid tangles and brain cell death that lead to the devastating neurodegenerative disease.
Cognoptix pulls in $15M Series D for Alzheimer's eye test
Cognoptix has pulled in more than $15 million in a Series D financing to advance an eye test for diagnosing Alzheimer's disease.
Developer of eye test for Alzheimer's raises $15M in VC round
Acton, MA-based Cognoptix, developer of an eye test for diagnosing Alzheimer's, announced that it has closed a Series D financing round worth more than $15 million. It was lead by new investor Alopexx and existing investor Inventages. Original investor Launchpad Venture Group also participated.
Pathway discovery reveals another potential Alzheimer's drug target
Researchers may have found the key to destroying the amyloid-β clumps long associated with Alzheimer's disease, which could spur new approaches to drug discovery in a field that has seen more than its share of failures.
Amarantus scores a small victory in the advance of its Alzheimer's Dx test
Alzheimer's watchers are left for the moment focusing on small victories. Amarantus Bioscience Holdings recently accomplished one, completing enrollment in a planned study of 72 patients to assess the feasibility of LymPro, its Alzheimer's blood diagnostic test.
Low levels of enzyme in Alzheimer's brains suggest new drug target
Many experimental Alzheimer's therapies have tried--and failed---to reverse or halt symptoms of the neurodegenerative disease by targeting the protein amyloid β in the brains of affected individuals. New research suggests that another culprit may be behind the development of Alzheimer's.
Survey says people want neurological diagnosis, regardless of cure
The argument for the importance of patient diagnosis often relies upon the efficacy of subsequent treatment. But according to a recent study, three-quarters of people would want to know if they have a particular neurological disorder even if it had no cure.
WENXUECITY.COM does not represent or guarantee the truthfulness, accuracy, or reliability of any of communications posted by other users.
Copyright ©1998-2024 wenxuecity.com All rights reserved. Privacy Statement & Terms of Use & User Privacy Protection Policy
